These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21623039)

  • 1. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
    Joseph P; Desai VB; Mohan NS; Fredrick JS; Ramachandran R; Raman B; Wares F; Ramachandran R; Thomas A
    Indian J Med Res; 2011 May; 133(5):529-34. PubMed ID: 21623039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
    Tripathy S; Anand A; Inamdar V; Manoj MM; Khillare KM; Datye AS; Iyer R; Kanoj DM; Thakar M; Kale V; Pereira M; Risbud AR
    Indian J Med Res; 2011 May; 133(5):521-8. PubMed ID: 21623038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
    Ramachandran G; Chandrasekaran V; Hemanth Kumar AK; Dewan P; Swaminathan S; Thomas A
    Trop Med Int Health; 2013 Sep; 18(9):1141-1144. PubMed ID: 23937703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
    Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
    Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India.
    Isaakidis P; Cox HS; Varghese B; Montaldo C; Da Silva E; Mansoor H; Ladomirska J; Sotgiu G; Migliori GB; Pontali E; Saranchuk P; Rodrigues C; Reid T
    PLoS One; 2011; 6(12):e28066. PubMed ID: 22145022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
    Dhingra VK; Rajpal S; Mittal A; Hanif M
    Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
    Singla R; Gupta S; Gupta R; Arora VK
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India.
    Paramasivan CN; Rehman F; Wares F; Sundar Mohan N; Sundar S; Devi S; Narayanan PR
    Int J Tuberc Lung Dis; 2010 Feb; 14(2):243-6. PubMed ID: 20074419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.
    Piparva KG; Jansari G; Singh AP
    Perspect Clin Res; 2018; 9(4):165-169. PubMed ID: 30319946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.
    Selvakumar N; Kumar V; Balaji S; Prabuseenivasan S; Radhakrishnan R; Sekar G; Chandrasekaran V; Kannan T; Thomas A; Arunagiri S; Dewan P; Swaminathan S
    PLoS One; 2015; 10(3):e0117421. PubMed ID: 25738956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.